Abbott Laboratories (Pakistan) Limited (ABOT): 9MCY24 Corporate Briefing Takeaways – By Taurus Research
Dec 17 2024
Taurus Securities
- ABOT is a prominent pharmaceutical company in Pakistan, renowned for its expertise in the manufacturing and marketing of a wide range of pharmaceutical products. With two state-of-the-art manufacturing facilities located in Karachi, ABBOT operates across diverse sectors, including diagnostics, pharmaceuticals, and nutrition, as well as general health and diabetes care. The Company maintains a balanced portfolio, with a 50-50 mix of essential and non-essential products, which adapts to market demand fluctuations, ensuring the availability of critical healthcare solutions.
- ABOT reported a PAT of ~PKR 4Bn for 9MCY24. This represents a significant improvement compared to a loss of ~PKR 793Mn during the same period last year. Despite the challenging economic conditions, ABBOT successfully maintained its market share, a testament to its resilience and strategic approach.
- Recent performance improvements are due to the strategic initiatives by Management and the de-regulation of non-essential products. Pharmaceutical sales grew 22% due to the strong performance of established brands, while the diagnostic segment expanded by 13% through new customer acquisitions. The nutritional segment was up 25% benefiting from price adjustments. These factors have enhanced profitability, with an 8% increase in margins.
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low